Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007
about
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparumArtesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malariaPlasmodium falciparum susceptibility to antimalarial drugs: global data issued from the Pasteur Institutes international networkThe interplay between drug resistance and fitness in malaria parasitesReview of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop reportA HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparumIn vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genesA novel flow cytometric hemozoin detection assay for real-time sensitivity testing of Plasmodium falciparumEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquinePlasmodium falciparum Choline Kinase Inhibition Leads to a Major Decrease in Phosphatidylethanolamine Causing Parasite DeathArtemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription.A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development.Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.Emerging artemisinin resistance in the border areas of Thailand.The outcome of a test-treat package versus routine outpatient care for Ghanaian children with fever: a pragmatic randomized control trialDrug-Resistant Malaria: The Era of ACT.Selective sweeps and genetic lineages of Plasmodium falciparum drug -resistant alleles in Ghana.Polymorphism of Plasmodium falciparum Na(+)/H(+) exchanger is indicative of a low in vitro quinine susceptibility in isolates from Viet Nam.Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.Decreasing pfmdr1 copy number suggests that Plasmodium falciparum in Western Cambodia is regaining in vitro susceptibility to mefloquineArtemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytesEx Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance.Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assayOptimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates.Mefloquine exposure induces cell cycle delay and reveals stage-specific expression of the pfmdr1 gene.Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia.Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria.A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan.Factoring quality laboratory diagnosis into the malaria control agenda for sub-Saharan Africa.Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia.Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.Four years' monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border.K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015.Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei.Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
P2860
Q21032477-CB81DC4C-B5DF-4D08-A8CA-39C676C95A71Q24198103-8F7347D3-5876-4E83-8323-A743287D6589Q26860875-18F603E1-E3D3-4827-A7DA-1D9116224B7EQ26998596-BBA1A9F3-677A-4FB2-8B25-651464F19DFDQ27024922-AFFC3747-92C2-4900-8219-473457B1AF8CQ27861949-095C0C2B-7641-4894-A324-D322515940E2Q28484068-98AF1825-8FF2-4A31-B65C-5AA45928A756Q28486811-3224ED48-D8AD-4A3F-83C0-A88E03C32B26Q28542034-07498B7A-BEA4-4727-9393-9B66D15FE055Q30040987-BDCE0F9C-B9B8-4A85-A573-66C778D68CA1Q33979085-02C7F1FD-FA9C-41B8-89DF-6BD9167F88C5Q34166626-95846B75-6DB8-45A1-B60D-121D459CCD9AQ34298916-2B1DC26D-A5BA-463A-86E3-59853E3377EAQ34343530-D8ED0A09-5398-4948-9564-7F5F8941432AQ34651041-B9879DB6-7633-4CBC-B994-797B85B8DF1EQ34681141-46C3371B-33C5-41CF-A3C2-BB2E303AC8E5Q34763548-C167511F-9E13-467A-A9B1-BCDEF1ACB976Q35069374-61785905-E821-4AE8-A060-7848CF4BFE35Q35137471-31EA7313-854F-465A-8755-F20BC29F9276Q35139464-46DFED92-6CF9-4F5C-9D81-AA5536D7B901Q35385674-739A2A1D-AC48-4690-AF7A-FE1A38A7BBC2Q35607727-2342E0E8-FEAA-4499-96A7-D56A4B9DC72AQ35859975-3BB713C4-42E3-43C0-9E03-EAF31A0D6D0DQ36112839-9734B24B-5F88-440D-B0EC-997446EC6112Q36372815-8F800D8A-7ABD-40C0-A3A2-D814CB78146BQ36558336-4CF785D0-BFED-4F9E-A775-A4DEEC559C2BQ36558472-D3A07CE5-4AD6-4296-A12B-C226354BA390Q36644779-B7A0EAD9-E4C8-4EA3-AEC2-4E255B7F5D58Q37153071-6473EF75-9339-4A56-AF39-4B8408C47B55Q37166071-1FD6A6BE-2563-4933-B954-A5869959A291Q37205700-284FFD9D-A1A0-4174-811D-8B2FFB6BC067Q37263344-AFBDAC29-E970-45FC-82B1-181D6FB7FFD4Q37366389-E93E5393-E008-4E0D-A93D-7408434A4A35Q37390583-AF1BAEDA-3AF2-4527-AC16-1D3154D833C6Q37496965-6AB65CB6-6379-42D8-A182-AA31AB6C1002Q41911890-88979B8E-6688-4E01-8809-04F6A681C4AEQ41920557-CB917DF4-AE41-4094-95BA-64D6D5E75389Q41929752-C85315F7-D78C-4142-BB1F-B38A253C9514
P2860
Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@ast
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@en
type
label
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@ast
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@en
prefLabel
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@ast
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@en
P2093
P2860
P50
P921
P356
P1476
Decreased in vitro susceptibil ...... in Cambodia from 2001 to 2007
@en
P2093
Chansuda Wongsrichanalai
Denis Mey Bouth
Frederic Ariey
Jean Gerard Gobert
Jean-Yves Coppee
Nimol Khim
Pascal Ringwald
Pheaktra Chim
Poravuth Yi
P2860
P304
P356
10.1128/AAC.01304-09
P407
P577
2010-03-01T00:00:00Z